Vanguard Capital Management’s Biogen BIIB Stock Holding History

Vanguard Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.09B	Buy	9,651,117 +113,700	+1%	+$21.7M	0.04%	315
2026 Q1	$1.75B	Buy	+9,537,417	New	+$1.76B	0.04%	343

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Vanguard Capital Management's BIIB Position: Q2 2026 in Review

Vanguard Capital Management increased its Biogen (BIIB) stake by 1.2% in Q2 2026, buying an estimated $21.7M and bringing the position to 9,651,117 shares worth $2.09B. The position accounts for 0.04% of the portfolio, ranked #315.

Vanguard Capital Management first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 981 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Vanguard Capital Management held 9,651,117 shares of Biogen worth $2.09B as of Q2 2026.
Vanguard Capital Management bought 113,700 Biogen shares in Q2 2026, an estimated $21.7M.
Biogen made up 0.04% of Vanguard Capital Management's portfolio in Q2 2026, its #315 holding.
Vanguard Capital Management first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
981 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.